News

Filter

Current filters:

PharmaceuticalBiosimilars

1 to 9 of 24 results

“Achievements and goals are endless in health care,” says head of Turkey’s AİFD

05-01-2015

Secretary general and chief operating officer of Turkey’s Association of Research-Based Pharmaceutical…

BiosimilarsHealthcarePharmaceuticalRegulationResearchTurkey

Rheumatologists have mixed views on Xeljanz's effect on structural damage and safety, but 80% prescribe it

Rheumatologists have mixed views on Xeljanz's effect on structural damage and safety, but 80% prescribe it

03-11-2014

Although 80% of rheumatologists surveyed by data and research firm Decision Resources Group prescribe…

Anti-Arthritics/RheumaticsBiosimilarsGlobalPfizerPharmaceuticalResearchXeljanz

Rheumatologists welcome novel biologics for systemic lupus erythematosus, survey finds

Rheumatologists welcome novel biologics for systemic lupus erythematosus, survey finds

16-10-2014

Rheumatologists would welcome novel biologics for the treatment of systemic lupus erythematosus (SLE),…

BenlystaBiosimilarsGlaxoSmithKlineHealthcareNeurologicalPharmaceuticalResearchUSA

Merck Serono on track with pharma strategy

Merck Serono on track with pharma strategy

18-09-2014

Germany’s Merck KGaA says that its biopharmaceutical division - Merck Serono - is well on track with…

ataciceptBiosimilarsFinancialGermanyImmunologicalsMerck KGaAMerck SeronoOncologyPharmaceuticalResearchTH-302

Opportunity for emerging agents in Crohn’s disease, report finds

Opportunity for emerging agents in Crohn’s disease, report finds

18-09-2014

New research from Decision Resources Group has found that only a small proportion of patients with Crohn's…

Anti-Arthritics/RheumaticsBiosimilarsEntyvioHumiraPharmaceuticalRemicadeResearchStelaraUSAXeljanz

Rheumatoid arthritis drug market will grow to $18.2 billion in 2023, report

17-09-2014

The rheumatoid arthritis (RA) disease-modifying antirheumatic drug market will increase from $14 billion…

Anti-Arthritics/RheumaticsbaricitinibBiosimilarsEli LillyEuropeIncyteJapanMarkets & MarketingPfizerPharmaceuticalUSAVertexXeljanz

EU approval for Boehringer and Lilly’s insulin glargine biosimilar

EU approval for Boehringer and Lilly’s insulin glargine biosimilar

10-09-2014

The European Commission granted marketing authorization for US drug major Eli Lilly and family-owned…

AbasriaBasaglarBiosimilarsBoehringer IngelheimDiabetesEli LillyEuropeInsulinLantusPharmaceuticalRegulationSanofi

1 to 9 of 24 results

COMPANY SPOTLIGHT

Menarini

Back to top